MONMOUTH JUNCTION, N.J., Feb. 4, 2016 /PRNewswire/ — CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader commercializing its flagship CytoSorb® blood filter to treat deadly inflammation in critically-ill and cardiac surgery patients around the world, announced that CEO Dr. Phillip Chan, MD, PhD, will present at the Source Capital Group’s 2016 Disruptive Growth & Healthcare Conference, providing an overview and update on the company.
Conference Presentation Details:
Where: Convene Conference Center, 730 Third Avenue, New York, NY 10017
When: Wednesday, February 10, 2016 at 8:30 AM ET
Room: Nolita Room
Conference Website: www.sourcecapitalconference.com
Currently, the management team is scheduling one-on-one meetings with registered investors through the conference’s meeting portal. To confirm, please contact Ms. Amy Vogel at firstname.lastname@example.org
About Source Capital Group’s 2016 Disruptive Growth & Healthcare Conference
The 2016 Disruptive Growth & Healthcare Conference will feature presentations from CEOs, CFOs, COOs and CMOs of life science companies focusing on solutions to unmet medical needs and growth companies with disruptive technologies and business models. Attendees will include over 400 institutional investors, accredited investors, family offices, analysts, registered investment advisors, wealth managers, Source reps and their clients. The panels will cover regenerative medicine, immunotherapy, diagnostics, disruptive innovations and business models, disruptive holding companies, energy – clean tech, technology media & telecom (TMT), and finally a discussion regarding NOLs and rights offerings. Presently Source has 8 offices, approximately 100 registered representatives, $750 million in assets, 10,000 retail accounts and is a SEC registered investment advisor. The conference is open to all Financial Advisors, Wealth Managers, Family Offices, Sell-Side Analysts, Institutional Investors, Accredited Investors, and Clients.
About CytoSorbents Corporation (NASDAQ: CTSO)
CytoSorb® is approved in the European Union with distribution in 32 countries around the world, as a safe and effective extracorporeal cytokine adsorber, designed to reduce the “cytokine storm” or “cytokine release syndrome” that could otherwise cause massive inflammation, organ failure and death in common critical illnesses such as sepsis, burn injury, trauma, lung injury, and pancreatitis, as well as in cancer immunotherapy. These are conditions where the risk of death is extremely high, yet no effective treatments exist. CytoSorb® is also being used during and after cardiac surgery to remove inflammatory mediators, such as cytokines and free hemoglobin, which can lead to post-operative complications, including multiple organ failure. CytoSorb® has been used safely in more than 9,000 human treatments to date.
CytoSorbents’ purification technologies are based on biocompatible, highly porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. The Company has numerous products under development based upon this unique blood purification technology, protected by 32 issued U.S. patents and multiple applications pending, including HemoDefend™, ContrastSorb, DrugSorb, and others. Additional information is available for download on the Company’s websites: https://cytosorbents.com and http://www.cytosorb.com
This press release includes forward-looking statements intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, statements about our plans, objectives, representations and contentions and are not historical facts and typically are identified by use of terms such as “may,” “should,” “could,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” “continue” and similar words, although some forward-looking statements are expressed differently. You should be aware that the forward-looking statements in this press release represent management’s current judgment and expectations, but our actual results, events and performance could differ materially from those in the forward-looking statements. Factors which could cause or contribute to such differences include, but are not limited to, the risks discussed in our Annual Report on Form 10-K, filed with the SEC on March 31, 2015, as updated by the risks reported in our Quarterly Reports on Form 10-Q, and in the press releases and other communications to shareholders issued by us from time to time which attempt to advise interested parties of the risks and factors which may affect our business. We caution you not to place undue reliance upon any such forward-looking statements. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, other than as required under the Federal securities laws.
(732) 329-8885 ext. *825
The Ruth Group
Public Relations Contact:
The Ruth Group
SOURCE CytoSorbents Corporation